Natco Q2 FY27: PAT down 61% YoY to ₹203 Cr (consolidated) as Lenalidomide fades
PAT -60.88% YoY · revenue -29.03% · margins compressing
₹967.3 Cr
-29.03% YoY
₹202.6 Cr
-60.88% YoY
19.87%
-15.5pp YoY
₹11.31
Natco Pharma's consolidated profit for Q2 FY27 came in at ₹202.6 Cr, down 60.9% year-on-year from ₹517.9 Cr and essentially flat quarter-on-quarter (-1.9% versus ₹206.5 Cr). Consolidated revenue from operations of ₹967.3 Cr fell 29.0% YoY but rose 31.6% QoQ. The YoY comparison is the one that matters here: Q2 FY26 was inflated by an exclusivity-driven Lenalidomide (generic Revlimid) spike in the US that has since normalised, and management's own press release attributes the YoY decline "largely" to lower Lenalidomide revenue, partly offset by growth in the base business and subsidiaries. International Formulations revenue (including subsidiaries) nearly halved YoY to ₹668.4 Cr from ₹1,140.2 Cr, even as it rose from ₹477.1 Cr in Q1 FY27 — the QoQ pickup looks like a stabilising base business, not a reversal of the structural Lenalidomide decline.
Q2 FY-2027 vs prior quarters
Margins compressed on both comparisons: EBITDA margin before share of associate fell to 30.4% from 46.4% a year ago (roughly flat versus 30.9% in Q1), and net margin on total income slid to about 19.9% from 35.4% YoY and 26.0% QoQ. The sequential margin stability, alongside a 31.6% QoQ revenue recovery, suggests the base pharmaceuticals and agrochemical businesses are no longer deteriorating quarter-on-quarter even as the YoY base effect from Lenalidomide persists. ₹29.2 Cr of the consolidated PAT came from NATCO's 49%-owned associate Adcock Ingram Holdings (South Africa, revenue ₹1,343.8 Cr, PAT ₹80.5 Cr for the quarter) — down from an unusually large ₹84.3 Cr associate contribution in Q1 that reflected provisional purchase-price-accounting adjustments after the stake increase; this makes the QoQ PAT comparison a little noisier than the headline flat print suggests. Standalone PAT of ₹143.2 Cr was down a sharper 71.4% YoY (versus consolidated's 60.9%), a double-digit-point divergence from the consolidated story driven mainly by the associate profit share and subsidiary earnings that sit outside the standalone entity — both numbers will circulate, and the gap is explained by consolidation scope, not a data error.
The stock went into the print at ₹782.45, down 0% over the past month of trading.
FY27: Revenue 3,400-3,500 Cr (but Q1 at 735 Cr annualizes to ~2,940 Cr); PAT 700-750 Cr (maintained despite Q1 weakness). Capex ~250-300 Cr/year ongoing.
— This quarter: missed
Against management's own FY27 guidance (revenue ₹3,400-3,500 Cr, PAT ₹700-750 Cr, given on the Q1 call under a cautious, high-risk tone), H1 FY27 revenue from operations of ₹1,702.5 Cr annualises to roughly ₹3,405 Cr — inside the guided band, a genuine improvement on the ~₹2,940 Cr pace flagged after Q1's weak start. PAT is murkier: H1 profit before the associate's share was ₹295.6 Cr, annualising to ~₹591 Cr, below the ₹700-750 Cr guided range; only once the outsized Q1 associate contribution is folded in does the H1 total of ₹409.1 Cr annualise above guidance (~₹818 Cr), a result that leans on a provisional, acquisition-related accounting item rather than recurring operations. On balance this reads as tracking below the PAT guidance on a core basis. We found no quarter-specific Street consensus for this print to grade against (vsStreet unknown); a web search surfaced only a full-year FY27 analyst estimate materially below even management's own guidance, underscoring that the market has been pricing a tougher outcome than the company's stated band. The quarter's corporate actions — a completed ₹1,279 Cr rights issue (1.7 Cr shares at ₹750 each) and a second interim dividend of ₹1.25/share declared alongside results — both land after the Lenalidomide-driven profit base has already reset lower, and tie to funding the expanded Adcock Ingram stake and the company's ongoing ₹250-300 Cr/year capex plan.
W1
Management has said Q2 FY27 was the last meaningful quarter for Lenalidomide, with Q3/Q4 contributions expected to be negligible — watch whether the base business can hold the ~₹967 Cr quarterly revenue run-rate without it.
W2
FY27 guidance of ₹700-750 Cr PAT implies H2 must deliver well above the ~₹591 Cr annualised core (ex-associate) run-rate seen in H1 — watch Q3 PAT for signs of a step-up.
W3
Adcock Ingram associate stake now at 49% with provisional PPA still being finalised — watch for the PPA to be trued up and the associate's profit contribution to normalise from Q1's elevated ₹84.3 Cr.
Figures converted from ₹ in millions (÷10). Consolidated PAT (₹202.6 Cr) = PBT−tax (₹173.4 Cr) + ₹29.2 Cr share of profit of associate Adcock Ingram (stake raised to 49% this quarter, provisional PPA); standalone arithmetic ties exactly. Prior-quarter/year-ago revenue, PAT and EPS all cross-checked to the exact decimal against the company's own comparative columns.
Can Natco stem the Revlimid cliff? Q2 revenue trajectory under watch
After a 43% revenue collapse in Q1, NATCO Pharma reports Q2 FY27 on Nov 13. The focus: whether the generic cancer drug Revlimid decline stabilizes or deepens, and if new US launches and capital raise can offset the headwind.
The setup: Generic Revlimid erosion and diversification in motion
NATCO Pharma's story has inverted. For years, the company banked on Revlimid (lenalidomide) — a high-margin cancer therapy whose generic launched in 2022 and was initially a growth engine. But US pricing competition and market saturation have turned it from profit generator to fading asset. Q1 FY27 showed the cliff: consolidated revenue crashed 43% YoY to ₹794 Cr, with Revlimid's decline the primary driver. The question on result day: did Q2 stabilize at a new run-rate, or did the erosion continue? And are new launches + geographic hedges (Adcock Ingram in SA, eGenesis biotech bets, Carboplatin ramp) enough to offset the cliff?
~₹900–950 Cr
Tracking Q1 run-rate (₹794 Cr); modest sequential recovery possible if Carboplatin and other launches contributed
~30–33%
Q1 was 26% vs historical 35%+; Revlimid cliff and increased R&D pressure margins; watch for cost controls
Steep decline continues
No recovery expected; question is decline rate — stabilized or accelerating?
~₹0.90–1.10
Reflecting lower profit and post-rights-issue share count dilution (equity base +9.5% from Oct allotment)
A strong Q2 would show revenue holding above ₹900 Cr, margins stabilizing above 30% despite the Revlimid cliff, and early ramp in Carboplatin + other new US launches. It would signal that management's cost discipline and new-product investments are beginning to offset the headwind. A weak Q2 would mean revenue falling further toward ₹800 Cr or below, margins compressing below 26%, and minimal contribution from new launches — suggesting the Revlimid cliff is steeper than expected and diversification is slower than guided.
On track?
FY27 is a reset year. Management guided for ₹3.33k Cr full-year revenue (−18.4% YoY), implying ~₹900–925 Cr average per quarter ex-one-offs. If Q2 lands in that range, the company stays on track. But FY26 full-year guidance was ₹4.3k Cr — a significantly higher bar than current expectations — so the Street has already repriced the trajectory downward. The stock is trading 50.76% below its all-time high (₹1,639), and analyst consensus has shifted to SELL, reflecting the reset. To move the needle, management must convince the Street that the ₹3.33k Cr base is defendable and that new products (especially Carboplatin, semaglutide ramp, and South Africa acquisitions) will begin offsetting Revlimid in H2 FY27.
What the Street says
Since last quarter
The past six weeks saw major capital and commercial moves:
Sept 25, 2026
Board approves ₹1,279 Cr rights issue at ₹750/share
Capital raise for M&A and CapEx; dilutes EPS by ~9.5% but gives firepower for growth
Sept 28, 2026
eGenesis investment increased to $24.7M total
Biotech hedge; regenerative medicine play outside core pharma; longer-term bet
Oct 12–22, 2026
Rights issue subscription period; allotment and trading window Oct 23–28
17.06 Cr shares allotted; equity base expanded; promoters pledged ~8.5L shares as part of the raise
Oct 19, 2026
Carboplatin Injection (generic Paraplatin) launched in US
New oncology generic entry; potential revenue contributor in H2/H3 quarters
Oct 30, 2026
Promoter V.C. Nannapaneni acquires 5.86L shares via rights issue
Promoter backing the raise; confidence signal, though modest dilution to stake (down from 49.56% to ~49.42%)
The rights issue is the biggest move — ₹1,279 Cr provides the cash cushion to fund Adcock Ingram integration, R&D, and potential M&A. The Carboplatin launch is material: it's a high-volume oncology drug with steady generic demand. Timing (mid-October) means minimal contribution to Q2, but it sets up H2 as a test of Natco's ability to execute launches and gain market share. The eGenesis bet is speculative — a long-term biotech hedge — but signals ambition beyond generics. Promoter participation in the rights issue is solid governance; the pledge and acquisition show confidence, though FII ownership has ticked down slightly (16.99% in Q1 FY27 vs 17.37% in Q4 FY26).
What to watch on Nov 13
1 · Revenue and Revlimid trajectory
Is Q2 revenue ₹900+ Cr, holding near Q1 run-rate? Or does it dip further, signaling ongoing cliff? Management will disclose product-wise breakup and any commentary on Revlimid volumes, pricing, and expected stabilization.
2 · Margin resilience
Did EBITDA margins recover toward 40%+ (prior historical range) or stay compressed below 35%? Watch for cost commentary — can management hold the line on OpEx while investing in new launches?
3 · New product contribution
What's the early uptake of Carboplatin, and are there other launches (semaglutide, other US generics) that management can highlight? These will shape confidence in H2 growth.
4 · FY27 guidance reiteration or reset
Does management stick with the ₹3.33k Cr full-year expectation, or signal further cuts? Any commentary on Adcock Ingram, eGenesis, or M&A integration timelines?
5 · Rights issue impact
Expect minimal direct benefit to Q2 (allotment was late Oct), but management commentary on how proceeds will be deployed (CapEx, Adcock Ingram, working capital) will matter for forward guidance.
6 · Dividend and capital allocation
Will the board declare a dividend on Q2? Q1 saw an interim dividend of ₹1.50/share despite the profit decline — signal of confidence or just policy?
NATCO Pharma stands at an inflection: the Revlimid cliff is real and ongoing, but management is mobilizing ₹1,279 Cr in fresh capital, rolling out new oncology generics, and hedging into biotech and South Africa. Q2 FY27 will reveal whether the company can stabilize revenue around ₹900 Cr and hold margins above 30% — a necessary first step to believing in the ₹3.33k Cr full-year guide and the Street's median ₹962 target price (19% above current).
The setup is binary: if Q2 shows revenue above ₹900 Cr, margin hold, and early wins from Carboplatin, the narrative shifts to execution and recovery play. If revenue dips below ₹800 Cr and margins fall further, the Street's SELL consensus will harden and the stock will face renewed pressure. Watch the Revlimid commentary carefully — management's expected stabilization timeline is the key variable.